Company Monitoring Page for Boehringer-Ingelheim

latest headlines for company on cafepharma

CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
Mon, 07/2/18 - 10:02 am
Tags:
CHMP, Boehringer Ingelheim, Eli Lilly, EMA, Jardiance, Synjardy, Glyxambi, diabetes
Mon, 07/2/18 - 09:26 am
Tags:
Boehringer Ingelheim, Eli Lilly, Jardiance, Synjardy, Glyxambi
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
Mon, 06/25/18 - 09:06 pm
Tags:
ADA, kidney disease, Eli Lilly, Boehringer Ingelheim
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Sun, 06/24/18 - 10:04 am
Tags:
Eli Lilly, Trulicity, Novo Nordisk, Ozempic, Boehringer Ingelheim, Jardiance, Tresiba, NovoRapid
Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires
Endpoints
Fri, 06/22/18 - 10:23 am
Tags:
Boehringer Ingelheim, R&D, Germany
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
Tags:
valrox, Biomarin, hepatitis A, risankizumab, AbbVie, Boehringer Ingelheim, psoriasis
Reversal Agent for Pradaxa, Praxbind, Now Available Nationwide
CP Wire
Fri, 05/4/18 - 06:48 pm
Tags:
Boehringer Ingelheim, Pradaxa, Praxbind
Fri, 05/4/18 - 10:22 am
Tags:
Boehringer Ingelheim, Pradaxa, Praxbind
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
Mon, 03/26/18 - 09:34 am
Tags:
social media, Novo Nordisk, JNJ, Novartis, Boehringer Ingelheim
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Wed, 03/7/18 - 12:00 pm
Tags:
Eli Lilly, Boehringer Ingelheim, Jardiance, heart failure, exercise, diabetes
Boehringer ends Alzheimer's research for PDE9 blocker
Biopharma Dive
Sat, 02/10/18 - 09:22 am
Tags:
Boehringer Ingelheim, Alzheimer's disease, PDE9 blockers, BI 409306
Boehringer strikes Jardiance outcomes deal with Prime PBM
Biopharma Dive
Thu, 02/1/18 - 09:55 am
Tags:
Boehringer Ingelheim, Jardiance, PBMs, diabetes, Prime Therapeutics, outcomes-based contracts
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Drug Delivery Business News
Mon, 01/29/18 - 03:20 pm
Tags:
Boehringer Ingelheim, PBMs, outcomes-based contracts, diabetes, Jardiance, Prime Therapeutics
Boehringer, hot on deals, adds another with Adimab collaboration
Biopharma Dive
Fri, 01/12/18 - 06:29 pm
Tags:
Boehringer Ingelheim, Adimab, drug discovery
Boehringer, BeiGene enter manufacturing pact for PD-1 drug
Biopharma Dive
Thu, 01/11/18 - 11:54 pm
Tags:
Boehringer Ingelheim, BeiGene, tislelizumab, anti-PD-L1, drug manufacturing
All in: Boehringer Ingelheim more than doubles its venture fund to €250M
Endpoints
Thu, 01/4/18 - 10:12 pm
Tags:
venture capital, Boehringer Ingelheim
Boehringer Ingelheim inks CNS deal with Autifony
BioPharma Dive
Tue, 12/19/17 - 11:59 am
Tags:
Boehringer Ingelheim, Autifony, CNS
Boehringer Ingelheim loses CFO due to disagreement on group’s strategy
GoinPharma
Sun, 12/17/17 - 11:30 am
Tags:
Boehringer Ingelheim
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
Fierce Pharma
Fri, 11/24/17 - 09:23 am
Tags:
JNJ, Eli Lilly, AstraZeneca, Boehringer Ingelheim, diabetes, Invokana, Farxiga, Jardiance
Boehringer Ingelheim denies rumors on acquisition of Korea’s CJ Healthcare ($896m)
GoinPharma
Fri, 11/17/17 - 10:22 am
Tags:
Boehringer Ingelheim, Korea, CJ Healthcare, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.